Protagenic Therapeutics, Inc.
PTIX
$0.218
-$0.0001-0.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.31% | 54.12% | -32.81% | -140.12% | -178.72% |
| Total Depreciation and Amortization | -52.63% | 800.00% | 12,500.00% | 12,500.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -60.00% |
| Total Other Non-Cash Items | -75.43% | 48.25% | -25.13% | -5.49% | 227.88% |
| Change in Net Operating Assets | 415.06% | -64.76% | 72.86% | -172.68% | -192.85% |
| Cash from Operations | 28.36% | 71.68% | -1.32% | -346.26% | -532.61% |
| Capital Expenditure | -- | -- | -- | -- | -5,122.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -100.00% | -0.74% | 308.18% | 1,349.88% |
| Cash from Investing | -100.00% | -100.00% | -0.74% | 308.18% | 1,307.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -55.56% | 90.91% | -71.43% | -60.00% | -98.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.02% | 298.49% | 14.71% | -494.65% | 1,894.02% |